Market closed·Syncing…
SMEMarket closed · Close · 17 Nov

Curis Lifesciences Limited CURISshare price and chart

Curis Lifesciences closed at ₹165.00 on 17 November 2026, down 0.60% on the day. The 52-week range is ₹83.60 to ₹234.75.

₹165.00The price one share last traded at, in rupees.▼ 0.60% · ₹1.00
52-wk low ₹8454% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹235

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on CURIS

Real prices, every charge counted. Pick one or write your own.
What Curis Lifesciences Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Curis Lifesciences develops, makes and distributes medicines, including tablets, capsules, liquid orals, creams, gels, ointments and sterile eye ointments, through contract manufacturing, loan licensing and its own brands, for customers in India and abroad.

1
1Sector

Pharmaceuticals & Biotechnology

2
2What it sells

Tablets, capsules, liquid orals, ointments, eye ointments

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 17 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
39Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
100%Near average
today 100%20d avg 92.5%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.▼ 10.0%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+28.1%1 monthHow much the share price has changed over the period.▼ 18.3%3 monthsHow much the share price has changed over the period.+47.3%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.55.2%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹133 Cr17 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.16.9xlast 4 quarters, to Sept 2026Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.2.59xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.15.5%full year FY26Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.00%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.39xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.-30.1%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Pharmaceuticals · 141 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.16.91vs 32.89 median
Cheapest: WALPAR 7.92Priciest: COHANCE 507.11
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.10.23%vs 10.14% median
Lowest: MEDIORG -86.72%Highest: SHUKRAPHAR 38.89%

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+23.2%over the last year
1 yr
+23.2%

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
68.03%promoter holding, as of 2026-09-30+0.0 pts since 2025
Promoter share since listing
2025-1168.03% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
68.0%
26.3%
Promoter68.0%Foreign (FII)1.1%Domestic (DII)4.6%Public & others26.3%
Who is buying, who is leavingNov 25 to Sep 26
Promoter68.0%steady
Foreign (FII)1.1%-1.9 pts
Domestic (DII)4.6%-6.2 pts

Each line is that holder's share of all shares over the last 3 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Updates16-Nov-2026

Curis Lifesciences Limited has informed the Exchange regarding 'Standalone andconsolidated financials results for the half year ended on 30th September, 2026'.

Statement of deviation(s) or variation(s) under Reg. 3211-Nov-2026

Curis Lifesciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32

Outcome of Board Meeting11-Nov-2026

Curis Lifesciences Limited has submitted to the Exchange, the standalone and consolidated financial results for the half year ended September 30, 2026.

Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter19-Oct-2026

Curis Lifesciences Limited has informed regarding Non-Applicability of the Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the Quarter and year ended on September 30, 2026

Certificate under SEBI (Depositories and Participants) Regulations, 201813-Oct-2026

Curis Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter and half year ended 30th September, 2026.

Shareholders meeting30-Sep-2026

Curis Lifesciences Limited has submitted the Exchange a copy Srutinizers report of 10th Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting results.

Shareholders meeting29-Sep-2026

CURIS: Curis Lifesciences Limited has informed the Exchange regarding Proceedings of 10thAnnual General Meeting held on September 29, 2026.

Trading Window23-Sep-2026

Curis Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Copy of Newspaper Publication08-Sep-2026

Curis Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication for Notice of 10th Annual General Meeting

Shareholders meeting07-Sep-2026

Curis Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026

Outcome of Board Meeting07-Sep-2026

Curis Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on September 07, 2026.

Resignation of Director/KMP/SMP03-Sep-2026

Curis Lifesciences Limited has informed the Exchange about Resignation of Director/KMP/SMP

Cessation03-Sep-2026

Curis Lifesciences Limited has informed the Exchange regarding Cessation of Mr Nikhil Purohit as Company Secretary & Compliance Officer of the company w.e.f. September 03, 2026.

Certificate under SEBI (Depositories and Participants) Regulations, 201819-Aug-2026

Curis Lifesciences Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on 30th June, 2026

Agreements13-Aug-2026

Curis Lifesciences Limited has informed the Exchange about Joint venture agreement entered into by the company with CUROSUN PHARMACEUTICAL NIG LTD (Nigerian Company) by acquiring 49.95% stake of such company.

Backtest idea · CURISMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on CURIS
Backtest idea · CURISLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on CURIS
Backtest idea · CURISSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on CURIS
Your own ideaWrite a rule for CURIS in plain English“Buy CURIS when …”
Start writing
Buy the dip on CURISBuy when RSI(14) drops below 30
52-week high breakout on CURISBuy when closes at a 52-week high
Golden cross on CURISBuy when 50-day EMA crosses above 200-day
Stochastic oversold on CURISBuy when stochastic %K drops below 20
Pullback in an uptrend on CURISBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹133 cr
Larger than 13% of 141 peers
sector middle ₹2,706 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
16.9x
Lower than 86% of 118 peers
sector middle 32.9x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
2.6x
Lower than 66% of 125 peers
sector middle 3.6x
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
15.5%
Around the middle of 124 peers
sector middle 14.9%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.39
Higher than 72% of 125 peers
sector middle 0.19
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.0%
Lower than 56% of 141 peers
sector middle 0.1%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash rose by ₹3 Cr, after ₹2 Cr spent on plant and equipment.

FY26Cash in or out
Running the business-₹16 Cr
Investing-₹2 Cr
Lenders and shareholders+₹21 Cr
Net change in cash+₹3 Cr

The full numbersSales and net profit by financial year or by quarter.

Backtest idea · CURISStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on CURIS
Backtest idea · CURISPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on CURIS
Backtest idea · CURISBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on CURIS
Backtest idea · CURIS52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on CURIS
Backtest idea · CURISGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on CURIS
MACD momentum on CURISBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on CURISBuy when closes below the lower Bollinger band
Supertrend rider on CURISBuy when supertrend turns up
Buy the dip on CURISBuy when RSI(14) drops below 30
52-week high breakout on CURISBuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Pharmaceuticals
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
SUNPHARMA
Sun Pharmaceutical Industries Limited
4.49 L cr41.0x5.0x14.7%19.1%0.0317.8%+11.9%0.85%
DIVISLAB
Divi's Laboratories Limited
2.93 L cr87.2x16.3x16.2%21.5%0.0027.6%+35.4%0.27%
TORNTPHARM
Torrent Pharmaceuticals Limited
1.75 L cr77.9x9.6x17.0%15.2%0.7612.1%+50.8%0.82%
LAURUSLABS
Laurus Labs Limited
1.25 L cr93.6x20.7x17.7%17.9%0.4017.0%+33.4%0.09%
ZYDUSLIFE
Zydus Lifesciences Limited
1.20 L cr28.9x4.3x18.3%19.9%0.4414.1%+29.2%0.08%
DRREDDY
Dr. Reddy's Laboratories Limited
1.17 L cr41.6x3.0x11.5%13.9%0.158.3%-1.5%0.57%
CIPLA
Cipla Limited
1.14 L cr39.5x3.2x11.7%16.0%0.0110.1%-2.4%0.92%
MANKIND
Mankind Pharma Limited
1.08 L cr48.3x6.2x12.4%12.9%0.3014.7%+17.3%0.00%
AUROPHARMA
Aurobindo Pharma Limited
1.03 L cr26.1x2.6x9.9%12.8%0.2110.8%+23.9%0.39%
LUPIN
Lupin Limited
90,173 cr17.3x3.8x26.9%28.8%0.2317.0%+11.1%0.91%
GLENMARK
Glenmark Pharmaceuticals Limited
74,679 cr51.5x6.7x14.1%20.4%0.089.2%-31.3%0.09%
ALKEM
Alkem Laboratories Limited
62,443 cr30.2x4.2x17.6%20.6%0.1213.4%+13.8%1.01%
BIOCON
Biocon Limited
58,987 cr215.4x1.7x1.1%3.0%0.411.9%+2.2%0.14%
ABBOTINDIA
Abbott India Limited
54,122 cr32.7x----23.0%+11.0%2.58%
GLAND
Gland Pharma Limited
53,307 cr43.1x5.0x10.5%15.0%0.0217.5%+23.3%0.62%
IPCALAB
IPCA Laboratories Limited
47,039 cr33.5x5.4x13.2%16.6%0.0614.2%+13.8%0.32%
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
44,693 cr39.5x23.8x48.9%66.5%0.0027.6%+20.8%2.16%
EMCURE
Emcure Pharmaceuticals Limited
44,294 cr40.5x8.3x19.6%24.8%0.2710.7%+24.3%0.15%
AJANTPHARM
Ajanta Pharma Limited
40,909 cr32.4x8.4x25.4%32.7%0.0220.3%+32.5%0.98%
SAILIFE
Sai Life Sciences Limited
37,978 cr100.5x14.1x15.1%20.9%0.1715.9%+22.5%0.00%
WOCKPHARMA
Wockhardt Limited
32,931 cr80.3x6.4x4.0%6.5%0.3910.8%+23.9%0.00%
ACUTAAS
Acutaas Chemicals Limited
32,677 cr74.4x17.6x23.5%31.7%0.0027.5%+42.7%0.06%
PPLPHARMA
Piramal Pharma Limited
31,813 cr-3.9x-4.0%0.8%0.69-2.1%+28.1%0.00%
NEULANDLAB
Neuland Laboratories Limited
27,527 cr60.8x13.6x21.4%27.5%0.1719.6%-12.6%0.16%
RUBICON
Rubicon Research Limited
27,450 cr84.1x19.4x19.1%23.4%0.2815.5%+39.9%0.09%
APLLTD
Alembic Pharmaceuticals Limited
20,528 cr24.3x3.5x12.4%11.7%0.259.9%+36.3%1.15%
GRANULES
Granules India Limited
19,762 cr27.6x3.0x13.5%15.7%0.0912.1%+20.3%0.22%
ERIS
Eris Lifesciences Limited
18,530 cr26.0x4.5x18.1%13.9%0.5821.6%+12.6%0.54%
ONESOURCE
Onesource Specialty Pharma Limited
18,189 cr-3.1x-1.3%0.4%0.25-0.1%+37.4%0.00%
SHILPAMED
Shilpa Medicare Limited
17,902 cr53.6x6.5x9.8%11.4%0.2418.1%+43.0%0.07%
ALIVUS
Alivus Life Sciences Limited
17,737 cr26.5x4.9x18.4%24.6%0.0024.9%+16.0%0.35%
PFIZER
Pfizer Limited
17,575 cr20.4x4.0x17.2%23.4%0.0032.4%+13.2%1.95%
COHANCE
Cohance Lifesciences Limited
17,462 cr507.1x4.5x5.1%8.0%0.06-0.3%-14.2%0.00%
NATCOPHARM
Natco Pharma Limited
16,098 cr17.7x1.6x16.9%17.1%0.1126.9%-29.0%0.70%
CAPLIPOINT
Caplin Point Laboratories Limited
15,851 cr23.0x4.1x19.9%24.7%0.0029.4%+17.9%0.38%
ASTRAZEN
AstraZeneca Pharma India Limited
15,109 cr85.0x17.2x22.8%31.2%0.006.8%+30.4%0.60%
JUBLPHARMA
Jubilant Pharmova Limited
14,870 cr56.2x2.1x6.0%8.7%0.542.9%+20.5%0.54%
CORONA
CORONA Remedies Limited
13,799 cr66.7x17.1x24.8%27.8%0.1213.3%+22.2%0.44%
MARKSANS
Marksans Pharma Limited
13,349 cr23.8x4.0x25.4%35.1%0.0116.7%+30.5%0.31%
CURIS
Curis Lifesciences Limited
133 cr16.9x2.6x-15.5%0.3910.2%-0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-13.3
-6.3
-5.2
+34.4
-5.5
-14.0
+11.3
+20.8
+59.1
-17.2
-8.3
·
+36.8%
11m
2025
·
·
·
·
·
·
·
·
·
·
·
-8.6
-8.6%
1m
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2026-03-06SIXTH SENSE SECURITIES PRIVATE LIMITED · bulkBUY93,000₹95.14₹0.88 Cr
2026-03-06RS SECURITIES · bulkSELL93,000₹95.05₹0.88 Cr
2026-01-05SS CORPORATE SECURITIES LIMITED · bulkBUY64,000₹129.55₹0.83 Cr
2026-01-05VINEY GROWTH FUND · bulkSELL42,000₹129.15₹0.54 Cr
2025-12-26SS CORPORATE SECURITIES LIMITED · bulkBUY61,000₹116.54₹0.71 Cr
2025-11-14PREETI BHAUKA · bulkBUY1,20,000₹146.10₹1.75 Cr
2025-11-14RADHU DEVELOPERS PRIVATE LIMITED · bulkBUY53,000₹143.00₹0.76 Cr
2025-11-14SACHIN KAPOOR · bulkBUY50,000₹146.10₹0.73 Cr

Read enough? Test CURIS. “Buy CURIS when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free